Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. More Details
Solid track record and good value.
Share Price & News
How has Probiotec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PBP is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PBP's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PBP underperformed the Australian Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: PBP underperformed the Australian Market which returned 11.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Probiotec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StProbiotec Limited (ASX:PBP) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
1 week ago | Simply Wall StProbiotec Limited (ASX:PBP) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
3 weeks ago | Simply Wall StKey Things To Understand About Probiotec's (ASX:PBP) CEO Pay Cheque
Is Probiotec undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PBP (A$2.24) is trading below our estimate of fair value (A$3.86)
Significantly Below Fair Value: PBP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PBP is good value based on its PE Ratio (28.4x) compared to the XO Pharmaceuticals industry average (74.7x).
PE vs Market: PBP is poor value based on its PE Ratio (28.4x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: PBP is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: PBP is good value based on its PB Ratio (2.6x) compared to the AU Pharmaceuticals industry average (3.6x).
How is Probiotec forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBP's forecast earnings growth (15.8% per year) is above the savings rate (2%).
Earnings vs Market: PBP's earnings (15.8% per year) are forecast to grow faster than the Australian market (15.4% per year).
High Growth Earnings: PBP's earnings are forecast to grow, but not significantly.
Revenue vs Market: PBP's revenue (14.3% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: PBP's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBP's Return on Equity is forecast to be low in 3 years time (14.7%).
How has Probiotec performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PBP has high quality earnings.
Growing Profit Margin: PBP's current net profit margins (5.6%) are higher than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: PBP's earnings have grown significantly by 23.4% per year over the past 5 years.
Accelerating Growth: PBP's earnings growth over the past year (31.7%) exceeds its 5-year average (23.4% per year).
Earnings vs Industry: PBP earnings growth over the past year (31.7%) exceeded the Pharmaceuticals industry 16.5%.
Return on Equity
High ROE: PBP's Return on Equity (8.8%) is considered low.
How is Probiotec's financial position?
Financial Position Analysis
Short Term Liabilities: PBP's short term assets (A$83.7M) exceed its short term liabilities (A$17.9M).
Long Term Liabilities: PBP's short term assets (A$83.7M) do not cover its long term liabilities (A$87.5M).
Debt to Equity History and Analysis
Debt Level: PBP's debt to equity ratio (75%) is considered high.
Reducing Debt: PBP's debt to equity ratio has increased from 18.3% to 75% over the past 5 years.
Debt Coverage: PBP's debt is not well covered by operating cash flow (19.7%).
Interest Coverage: PBP's interest payments on its debt are well covered by EBIT (4.8x coverage).
What is Probiotec current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PBP's dividend (2.01%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.08%).
High Dividend: PBP's dividend (2.01%) is low compared to the top 25% of dividend payers in the Australian market (5.35%).
Stability and Growth of Payments
Stable Dividend: PBP's dividend payments have been volatile in the past 10 years.
Growing Dividend: PBP's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (63.4%), PBP's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PBP's dividends in 3 years are forecast to be well covered by earnings (47.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Wesley Stringer, also known as Wes, B.Comm (Accounting, Finance), LLB (Hons), CPA, has been the Chief Executive Officer of Probiotec Limited since July 1, 2015 and serves as its managing Director. Mr. ...
CEO Compensation Analysis
Compensation vs Market: Wes's total compensation ($USD416.27K) is above average for companies of similar size in the Australian market ($USD293.87K).
Compensation vs Earnings: Wes's compensation has increased by more than 20% in the past year.
|CEO, MD & Executive Director||5.67yrs||AU$535.29k||6.31% |
|Independent Chairman||0.67yr||AU$53.33k||0.23% |
|Independent Non-Executive Director||4.08yrs||AU$54.67k||0.14% |
|Non-Executive Director||0.75yr||AU$4.83k||0.090% |
Experienced Board: PBP's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.
Probiotec Limited's company bio, employee growth, exchange listings and data sources
- Name: Probiotec Limited
- Ticker: PBP
- Exchange: ASX
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$174.973m
- Shares outstanding: 78.46m
- Website: https://www.probiotec.com.au
- Probiotec Limited
- 83 Cherry Lane
- Laverton North
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PBP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Nov 2006|
|PBP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Nov 2006|
Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. The company provides contract manufactur...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/02 07:05|
|End of Day Share Price||2021/03/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.